Two abstracts accepted for oral presentation at the 13th London International Cough Symposium NEW HAVEN, Conn., July 2, 2024 /PRNewswire/ — Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine…